Executive Summary
The PTAB instituted an inter partes review of Inari Medical’s hemostasis valve patent after Imperative Care showed a reasonable likelihood of success, focusing on the definition of “filament” and its flexibility versus prior art.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Imperative Care, Inc. vs Inari Medical, Inc. et al. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Red Hat, Inc.vsCompetitive Access Systems, Inc.
Red Hat petitions the PTAB to invalidate Competitive Access Systems’ 8,228,801 patent, asserting that all 17 claims are obvious over earlier bandwidth‑sharing technologies. The petition relies on the Challener and Kotzin disclosures, with Held providing motivation for routing‑table features.
Terumo BCT, Inc.vsHaemonetics Corporation
Haemonetics Corp. seeks Director review to vacate the institution of an IPR filed by Terumo BCT over its plasma‑apheresis patent. The Owner argues the petitioner’s inconsistent claim‑construction positions and failure to comply with 37 C.F.R. § 42.104(b)(3) warrant denial. The request cites recent Director precedents to support vacatur.
Samsung Electronics Co., Ltd. et al.vsHEADWATER RESEARCH LLC
Samsung and HEADWATER reached a settlement, leading to a joint motion to terminate IPR2025-00483 and related proceedings. The petitioner withdrew its request for Director Review.
Apple Inc.vsApex Beam Technologies LLC
Apple has filed an IPR petition seeking to invalidate Apex Beam’s 5G beam‑failure patent (U.S. 11637615). The challenger alleges obviousness over Cirik, Wu and InterDigital references, covering all 16 claims. The petition requests institution and argues no discretionary denial is warranted.
Apple Inc.vsCardWare Inc.
The USPTO Director denied the institution of IPR proceedings, including one involving Apple Inc., meaning no trial will proceed on the challenged patent claims.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.